|   |   | 
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| A61K 35/74 | |||
| A61P 35/00 | 
| (11) | Number of the document | 3319635 | 
| (13) | Kind of document | T | 
| (96) | European patent application number | 16734013.2 | 
| Date of filing the European patent application | 2016-06-24 | |
| (97) | Date of publication of the European application | 2018-05-16 | 
| (45) | Date of publication and mention of the grant of the patent | 2021-04-21 | 
| (46) | Date of publication of the claims translation | 
| (86) | Number | PCT/GB2016/051893 | 
| Date | 2016-06-24 | 
| (87) | Number | WO 2016/207646 | 
| Date | 2016-12-29 | 
| (30) | Number | Date | Country code | 
| 201511120 | 2015-06-24 | GB | |
| 201511121 | 2015-06-24 | GB | 
| (72) | 
                    
                    
                    
                    
                    AKLE, Charles, GB  
                    
                    
                    
                    
                    BRUNET, Laura Rosa, GB  | 
| (73) | Immodulon Therapeutics Limited,
                6-9 The Square  Stockley Park, Uxbridge UB11 1FW,
                GB | 
| (54) | A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY | 
| A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY |